Alpine Global Management’s Inovio Pharmaceuticals INO Stock Holding History

Alpine Global Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-33,812	Closed	-$61.9K	–	194
2024 Q4	$61.9K	Buy	+33,812	New	+$150K	0.01%	202
2024 Q3	–	Sell	-24,916	Closed	-$201K	–	296
2024 Q2	$201K	Buy	+24,916	New	+$262K	0.04%	307
2023 Q1	–	Sell	-6,348	Closed	-$119K	–	288
2022 Q4	$119K	Buy	+6,348	New	+$144K	0.04%	173
2022 Q1	–	Sell	-1,437	Closed	-$86K	–	578
2021 Q4	$86K	Buy	+1,437	New	+$115K	0.01%	690
2020 Q4	–	Sell	-1,667	Closed	-$232K	–	252
2020 Q3	$232K	Buy	+1,667	New	+$348K	0.05%	146
2014 Q2	–	Sell	-322	Closed	-$51K	–	201
2014 Q1	$51K	Buy	+322	New	+$46.2K	0.04%	144

Other funds holding INO

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alpine Global Management's INO Position: Q1 2025 in Review

Alpine Global Management sold out of Inovio Pharmaceuticals (INO) in Q1 2025, closing a stake of 33,812 shares — an estimated $61.9K sold.

Alpine Global Management first reported a position in INO in Q1 2014 and held it in 6 quarters. The position peaked at $232K in Q3 2020. 107 funds tracked by Wall St. Rank hold INO as of Q1 2025.

Alpine Global Management reported no remaining Inovio Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Alpine Global Management sold 33,812 Inovio Pharmaceuticals shares in Q1 2025, an estimated $61.9K.
Alpine Global Management first reported a position in Inovio Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Alpine Global Management's Inovio Pharmaceuticals position peaked at $232K in Q3 2020.
107 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.